Skip to main navigation

Back

Contact Revance
Login

Menu

Aesthetics
Back Aesthetics
Visit Site
Therapeutics
Back Therapeutics
Investors
Back Investors
LATEST NEWS
In the News

April 27, 2021

Experts Call These the Most Cutting-Edge Aesthetic Treatments

InStyle

All News
Company
Back Company
OUR LATEST
In the News

April 27, 2021

Experts Call These the Most Cutting-Edge Aesthetic Treatments

InStyle

Our Latest
News
Careers
Back Careers

facebook
instagram
twitter
linkedin

1222 Demonbreun St
20th Floor
Nashville, TN 37203

Contact Revance
Login

© Copyright 2022

All Rights Reserved

Breadcrumb

Home
Investors
Press releases

Press Releases

Press Releases

Items Per Page

Year

December 5, 2019

Revance Announces Publication of Pooled Results from Phase 3 Trials for Glabellar Lines in the Journal of the American Academy of Dermatology

December 4, 2019

Revance Announces Pricing of Public Offering of Common Stock

December 3, 2019

Revance Announces Proposed Public Offering of Common Stock

December 2, 2019

Revance Promotes Dustin Sjuts to Chief Commercial Officer, Aesthetics & Therapeutics

November 25, 2019

Revance Submits Biologics License Application (BLA) to the FDA for DAXI to Treat Glabellar (Frown) Lines

November 12, 2019

Revance to Participate in the Stifel 2019 Healthcare Conference

November 6, 2019

Revance to Participate in the Credit Suisse 28th Annual Healthcare Conference

November 4, 2019

Revance Reports Third Quarter 2019 Financial Results, Provides Corporate Update

November 4, 2019

Revance Completes Enrollment in ASPEN-1 Phase 3 Pivotal Trial for Cervical Dystonia

November 4, 2019

Revance Announces Publication of SAKURA 1 and SAKURA 2 Results in Plastic and Reconstructive Surgery

Pagination

First page
Previous page
…
Page 5
Page 6
Page 7
Page 8
Current page 9
Page 10
Page 11
Page 12
Page 13
…
Next page
Last page

Displaying 81 - 90 of 268

Investor Relations

Investor Relations
Press Releases
Events & Presentations
- Events
- Presentations and Corporate Materials
Corporate Governance
Financials & Filings
Stock Information
Analyst Coverage
Investor FAQs
Contact Us

image description

Revance - Shareholder Tools

Print Page
Printed Materials
Email Alerts
Download Library
RSS News Feeds
Share
Search

Keep up with Revance

Subscribe

1222 Demonbreun St
20th Floor
Nashville, TN 37203

facebook
instagram
twitter
linkedin

Aesthetics

Overview
RHA®
OPUL
Neuromodulator
Neuromodulator Uses
Clinical Highlights

Therapeutics

Overview
Cervical Dystonia
Upper Limb Spasticity
Plantar Fasciitis
Clinical Highlights

Investors

Investor Relations
Press Releases
Events & Presentations
Corporate Governance
Financials & Filings
Stock Information
Analyst Coverage
Investor FAQ
Contact Us

Company

Overview
About Revance
Leadership Team
Board of Directors
Partnerships
Investigator Sponsored Trials
Medical Education Grants
Sustainability
Contact Revance

News

All News
In the News
Our Latest

Careers

Overview
Career Opportunities
Culture
Benefits & Perks
Privacy Notice

© Copyright 2022
All Rights Reserved
Terms of Use
Privacy Policy
Corporate Social Media Community Guidelines

Facebook
LinkedIn